Pneumocystis jirovecii colonization among renal transplant recipients

Nephrology

Volumn 18, Issue 5, 2013, Pages 382-387

  Fritzsche, Carlos ^a   Riebold, Diana ^a   Fuehrer, Andreas ^a   Mitzner, Andrea ^a   Klammt, Sebastian ^a   Mueller Hilke, Brigitte ^a   Reisinger, Emil C ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

immunosuppression; Pneumocystis jirovecii; pulmonary colonization; renal transplantation

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; FUNGAL COLONIZATION; FUNGUS TRANSMISSION; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPUTUM ANALYSIS;

ADULT; AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LUNG; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; RISK FACTORS; TIME FACTORS;

EID: 84876464015     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12054     Document Type: Article

References (39)

1. Monnet X, Vidal-Petiot E, Osman D, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit. Care 2008; 12: R28.
2. Goto N, Oka S,. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl. Infect. Dis. 2011; 13: 551-558.
3. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 2004; 10: 1713-1720.
4. Saksasithon S, Sungkanuparph S, Thanakitcharu S,. Pneumocystis carinii pneumonia in patients without HIV infection. J. Med. Assoc. Thai. 2003; 86: 612-616.
5. Lufft V, Kliem V, Behrend M, Pichlmayr R, Koch KM, Brunkhorst R,. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation 1996; 62: 421-423.
6. Shelton E, Yong M, Cohney S,. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology (Carlton) 2009; 14: 696-699.
7. Eitner F, Hauser IA, Rettkowski O, et al. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol. Dial. Transplant. 2011; 26: 2013-2017.
8. Le Gal S, Damiani C, Rouille A, et al. A cluster of Pneumocystis infections among renal transplant recipients: Molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin. Infect. Dis. 2012; 54: e62-71.
9. McCaughan JA, Courtney AE,. Pneumocystis jiroveci pneumonia in renal transplantation: Time to review our practice? Nephrol. Dial. Transplant. 2012; 27: 13-15.
10. Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: A case-control study. Transpl. Infect. Dis. 2003; 5: 84-93.
11. European Best Practice Guidelines for Renal Transplantation. Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol. Dial. Transplant. 2002; 17 (Suppl 4): 36-39.
12. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am. J. Transplant. 2009; 9 (Suppl 3): S1-155.
13. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S,. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 2009; 88: 380-385.
14. Gianella S, Haeberli L, Joos B, et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl. Infect. Dis. 2010; 12: 1-10.
15. Arichi N, Kishikawa H, Mitsui Y, et al. Cluster outbreak of Pneumocystis pneumonia among kidney transplant patients within a single center. Transplant. Proc. 2009; 41: 170-172.
16. Phipps LM, Chen SC, Kable K, et al. Nosocomial Pneumocystis jirovecii pneumonia: Lessons from a cluster in kidney transplant recipients. Transplantation 2011; 92: 1327-1334.
17. Chabe M, Dei-Cas E, Creusy C, et al. Immunocompetent hosts as a reservoir of pneumocystis organisms: Histological and rt-PCR data demonstrate active replication. Eur. J. Clin. Microbiol. Infect. Dis. 2004; 23: 89-97.
18. Miller RF, Ambrose HE, Wakefield AE,. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J. Clin. Microbiol. 2001; 39: 3877-3882.
19. Morris A, Kingsley LA, Groner G, Lebedeva IP, Beard CB, Norris KA,. Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS 2004; 18: 793-798.
20. Medrano FJ, Montes-Cano M, Conde M, et al. Pneumocystis jirovecii in general population. Emerg. Infect. Dis. 2005; 11: 245-250.
21. Fritzsche C, Riebold D, Munk-Hartig A, Klammt S, Neeck G, Reisinger E,. High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy. Scand. J. Rheumatol. 2012; 41: 208-213.
22. Riebold D, Mohr E, Sombetzki M, Fritzsche C, Loebermann M, Reisinger EC,. Pneumocystis species in Brown Leghorn laying hens-a hint for an extra-mammalian reservoir. Poult. Sci. 2012; 91: 1813-1818.
23. Riebold D, Hennig A, Loebermann M, Schareck W, Reisinger EC,. Pneumocystis pneumonia in an alcoholic patient with prolonged mechanical ventilation. Eur. J. Clin. Microbiol. Infect. Dis. 2005; 24: 294-296.
24. Savoia D, Millesimo M, Cassetta I, Forno B, Caramello P,. Detection of Pneumocystis carinii by DNA amplification in human immunodeficiency virus-positive patients. Diagn. Microbiol. Infect. Dis. 1997; 29: 61-65.
25. Mori S, Cho I, Ichiyasu H, Sugimoto M,. Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: A possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy. Mod. Rheumatol. 2008; 18: 240-246.
26. Morris A, Wei K, Afshar K, Huang L,. Epidemiology and clinical significance of pneumocystis colonization. J. Infect. Dis. 2008; 197: 10-17.
27. de Boer MG, Kroon FP, le Cessie S, de Fijter JW, van Dissel JT,. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl. Infect. Dis. 2011; 13: 559-569.
28. Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S,. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol. Int. 2009; 29: 491-496.
29. Kadoya A, Okada J, Iikuni Y, Kondo H,. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J. Rheumatol. 1996; 23: 1186-1188.
30. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H,. Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000; 118: 712-720.
31. Nevez G, Raccurt C, Vincent P, Jounieaux V, Dei-Cas E,. Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: Assessing risk with blood CD4+ T cell counts. Clin. Infect. Dis. 1999; 29: 1331-1332.
32. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC,. Analysis of USRDS: Incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88: 135-141.
33. Wissmann G, Morilla R, Martin-Garrido I, et al. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur. J. Clin. Invest. 2011; 41: 343-348.
34. Beck JM, Cushion MT,. Pneumocystis workshop: 10th anniversary summary. Eukaryot. Cell 2009; 8: 446-460.
35. Miguez-Burbano MJ, Ashkin D, Rodriguez A, et al. Increased risk of Pneumocystis carinii and community-acquired pneumonia with tobacco use in HIV disease. Int. J. Infect. Dis. 2005; 9: 208-217.
36. Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin. Infect. Dis. 1996; 22: 920-925.
37. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German study group on mycophenolate mofetil therapy. J. Am. Soc. Nephrol. 2002; 13: 759-768.
38. Bergrem H, Jervell J, Flatmark A,. Prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients. Kidney Int. 1985; 27: 459-464.
39. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther. Drug Monit. 2003; 25: 609-622.